How does the mouse CD206 antibody reveal the role of macrophages in the occurrence of myopia?

1. Why Focus on Sclera and Immune Cells in Myopia Research?

Myopia is the most common refractive error worldwide, characterized pathologically by excessive elongation of the eyeball axis, causing parallel light rays to focus in front of the retina. The development of myopia involves complex biological processes, with the posterior sclera—a key structure in the outermost layer of the eyeball wall—playing a critical role. Its biomechanical properties and remodeling processes are considered the final effector steps in axial elongation. Recent studies suggest that myopia formation may be linked to localized or systemic low-grade chronic inflammation, but the specific causal relationships and molecular mechanisms remain unclear. Macrophages, as core cells of the innate immune system, play multifaceted roles in maintaining tissue homeostasis, injury repair, and inflammation regulation. They exhibit high plasticity, polarizing into pro-inflammatory M1-type or anti-inflammatory/repair M2-type phenotypes based on microenvironmental signals. Therefore, investigating macrophages in scleral tissue—particularly identifying subsets through specific markers like the M2 marker CD206—provides a new entry point for understanding the role of the immune microenvironment in scleral remodeling and myopia progression. High-specificity mouse CD206 antibodies are indispensable tools for unraveling this scientific question.

2. How to Establish and Evaluate a Form-Deprivation Myopia Model?

To explore the dynamic changes of macrophages in myopia development, researchers often use the form-deprivation method to establish a mouse myopia model. This method induces myopic refractive changes in the covered eye by artificially blurring visual input through unilateral eye occlusion. A typical experimental design involves randomly grouping young mice of the same age into a form-deprivation group (unilateral eye occlusion), an internal control group (contralateral uncovered eye), and a normal blank control group. Quantitative assessment of myopia induction is performed through refractive error measurements and axial length detection at specific time points (e.g., before the experiment, 14 days post-occlusion, and 28 days post-occlusion). Research data show that after 28 days of form deprivation, the occluded eye exhibits significant myopic refractive shifts and axial elongation compared to the control eye, confirming the model's validity. This model provides a standardized system for observing cellular and molecular events in scleral tissue during myopia progression, particularly immune cell infiltration and phenotypic shifts, within a defined time window.

3. How Is the CD206 Antibody Applied in Flow Cytometry Analysis?

Flow cytometry is a powerful technique for quantitatively analyzing the proportions and phenotypes of specific cell subsets in tissues. When studying macrophages in scleral tissue, the posterior sclera must first be finely dissected and prepared as a single-cell suspension. Subsequently, cells are stained with fluorescently labeled antibodies. In this process, the combined use of mouse CD206 antibodies (typically monoclonal antibodies against mouse CD206/MMR) and the universal macrophage marker F4/80 is crucial. CD206, the macrophage mannose receptor, is a recognized surface marker for M2-type macrophages. Flow cytometry enables precise differentiation and quantitative analysis of the total population of F4/80-positive macrophages in scleral tissue, as well as the proportion of the M2 subset co-expressing F4/80 and CD206. This dual-labeling strategy allows researchers to dynamically monitor changes in overall macrophage infiltration levels and M2 polarization states in the sclera during myopia development.

4. What Dynamic Changes Occur in Scleral Macrophages During Myopia Development?

Using the above methods, studies have found that myopia progression induced by form deprivation is accompanied by significant changes in posterior scleral macrophages. At 14 days of form deprivation, although refractive error and axial length show no statistical differences, the total number of F4/80-positive macrophages and the proportion of F4/80/CD206 double-positive macrophages (M2-type) in the posterior sclera of the occluded eye are significantly higher than in the control eye. By 28 days of form deprivation, when myopic refractive shifts and axial elongation are clearly established, the proportion of F4/80/CD206 double-positive macrophages in the occluded eye's sclera not only remains higher than in the control eye but also increases significantly compared to its own levels at 14 days. Importantly, correlation analysis reveals that at the 28-day time point, the percentage of F4/80/CD206 double-positive macrophages in the posterior sclera is negatively correlated with myopic refractive error and positively correlated with axial length. These data clearly demonstrate that during form-deprivation myopia, the posterior sclera exhibits immune cell infiltration characterized by an increase in M2-type macrophages. This change precedes obvious axial elongation and is closely associated with myopia severity.

5. What Is the Potential Significance of Increased M2-Type Macrophages in Myopia Development?

Research findings suggest that the increase in M2-type macrophages is not a passive consequence of myopia but may actively participate in regulating scleral remodeling. M2-type macrophages are classically considered to have anti-inflammatory, tissue-repair, and fibrotic functions. In the context of myopia development, their sustained increase may influence scleral fibroblast activity by secreting various cytokines, growth factors (e.g., TGF-β, PDGF), and matrix metalloproteinases, thereby altering the balance of extracellular matrix (especially collagen fibers and proteoglycans) synthesis and degradation. This could change the biomechanical properties of the sclera, ultimately promoting scleral expansion and axial elongation. Studies using mouse CD206 antibodies isolate this specific macrophage subset from the complex immune microenvironment, laying the foundation for functional research.

6. Which Manufacturers Provide Mouse CD206 (MMR) Antibodies?

Hangzhou Start Biotech Co., Ltd. has independently developed the "Rat Anti-Mouse CD206 (MMR) Antibody (S-R498)" (Catalog No.: S0B1295), a high-specificity, high-affinity, and highly stable antibody for detecting M2-type macrophage polarization markers. This product uses high-quality rat monoclonal antibodies to efficiently and specifically bind mouse CD206 (macrophage mannose receptor, MMR). It performs excellently in flow cytometry (FACS), immunohistochemistry (IHC), and immunofluorescence (IF), making it a key tool for studying macrophage polarization, tumor immune microenvironments, and inflammatory diseases.

Technical Support: We provide detailed technical parameters for this product, including recommended concentrations, applicable sample types (cell suspensions, tissue sections), and suggestions for multicolor flow cytometry panels. Our technical team offers professional consultations.

Hangzhou Start Biotech Co., Ltd. is committed to providing high-performance, high-quality antibody reagents for mouse model immunology research. For more details about the "Rat Anti-Mouse CD206 (MMR) Antibody" (Catalog No. S0B1295), validation data, or sample requests, please contact us.

Product Information

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.